Latest news with #neuroblastoma
Associated Press
27-05-2025
- Business
- Associated Press
Preclinical Data on Circle Pharma's CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 27, 2025-- Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C., May 25-28, 2025. The data, which explore the therapeutic potential of CID-078 in neuroblastoma (NB), were presented in a poster entitled: The poster highlights the work of researchers from the Princess Máxima Center for Pediatric Oncology (Utrecht, the Netherlands), the Hopp Children's Cancer Center Heidelberg (KiTZ) (Heidelberg, Germany), and Circle Pharma, demonstrating the potent anti-tumor activity of CID-078 in preclinical neuroblastoma (NB) models. CID-078 is a first-in-class oral macrocycle cyclin A/B RxL inhibitor that selectively disrupts RxL-mediated interactions between cyclin A2/B1 and their substrates, a novel mechanism of action that targets cell cycle dysregulation in cancer. In neuroblastoma, where CDK-RB-E2F axis deregulation and oncogenic E2F activity are common, this mechanism is particularly relevant. Key Findings Presented: Potent Single agent CID-078 activity was observed across multiple neuroblastoma cell line models. Mechanism of action studies confirmed induction of DNA damage, G2/M arrest and the activation of the spindle assembly checkpoint (SAC). Deletion of CDKN2A sensitized cells to CID-078 suggesting CDKN2A status maybe be used as a potential patient stratification strategy. 'A greater understanding of the biology of neuroblastoma, the most common extra-cranial solid tumor diagnosed in children, has shown specific genomic alterations which deregulate the cell cycle leading to E2F activation,' said Michael C. Cox, PharmD, MHSc, BCOP, SVP and head of early development of Circle Pharma. 'Circle's collaboration with these two premier pediatric oncology research institutions has shown again the potential of our macrocycle platform to develop new therapies for historically challenging targets. The exciting CDKN2A deletion biomarker data, as well as the in vitro data in a pediatric tumor with a need for better treatments support our clinical development plans for CID-078.' The full poster is available here. About CID-078, Circle Pharma's Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial ( NCT06577987 ) is currently enrolling patients. About Circle Pharma, Inc. South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial ( NCT06577987 ) for patients with advanced solid tumors. To learn more about Circle Pharma, please visit View source version on CONTACT: Media Contact: Roslyn Patterson Phone: 650.825.4099 Email: [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA DISTRICT OF COLUMBIA INDUSTRY KEYWORD: RESEARCH VENTURE CAPITAL GENETICS CLINICAL TRIALS PROFESSIONAL SERVICES BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE ONCOLOGY SOURCE: Circle Pharma, Inc. Copyright Business Wire 2025. PUB: 05/27/2025 07:05 AM/DISC: 05/27/2025 07:05 AM
Yahoo
27-05-2025
- Business
- Yahoo
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The presentation marks a significant update in its experimental pipeline. The trial-in-progress poster contained findings from Trial 1001, a Phase 1 study assessing GD2-SADA Pretargeted Radioimmunotherapy using 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2-expressing tumors. A scientist in a lab coat, holding a beaker of a biopharmaceutical creation. The focus of the company's presentation was on radioimmunotherapy innovation. The GD2-SADA construct, developed in a partnership with Memorial Sloan Kettering Cancer Center, deploys a two-step process allowing localized irradiation of tumors while limiting off-target toxicity. Trial 1001 has now completed Part A and has identified the optimal dosage for the GD2-SADA protein. It is currently being prepared for further evaluation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has scheduled to deliver its initial data readout during its virtual R&D update on May 28. The company's stock gained 5.37% in the past week right before the new unveiling, reflecting investor confidence in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s proprietary Self-Assembly DisAssembly (SADA) platform as well as the upcoming clinical milestones. Analysts remain bullish, offering a consensus Buy rating, while projecting an average price target of $16.50 with an upside potential of 281.94%. While we acknowledge the potential of YMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than YMAB and that has 100x upside potential, check out our report about the READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
25-05-2025
- Health
- Washington Post
More kids are beating cancer. Improving the rest of their lives is next.
When oncologists gave my 5-year-old daughter the all-clear from high-risk neuroblastoma in 2010, I breathed a sigh of relief. But her health needs were just beginning. Fifteen years later, the intense and often toxic treatments that saved Emily's life have left her with a host of lifelong health challenges — hearing loss, stunted height, endocrine and kidney dysfunction, and permanent hair-thinning — issues no one talked about during her 18 months of cancer treatment.
Yahoo
09-05-2025
- Sport
- Yahoo
Family fun day at Darlington rugby club in memory of inspirational Luke Bell
Rugby fans are being urged to support a fundraiser in memory of an inspirational eight-year-old boy. The TeamLuke Foundation is hosting a family funday on Saturday, 10 May, at Blackwell Meadows, the home of Darlington Rugby Club. The event will raise money for research into childhood cancers, adding to the £250,000 already raised by the charity in memory of Luke Bell. Luke Bell (Image: Supplied) Luke fought neuroblastoma for 21 months before passing away on 23 December 2018. The fund finances a researcher at the Institute of Cancer Research and raises awareness about the condition, as well as providing support to parents and enhancing the diagnosis and treatment of neuroblastoma. Organisers hope that as many as 1,000 people and 100 players will attend the funday, which will feature giant inflatables, food and drink, charity rugby matches, and live music. Team Luke Women's Rugby (Image: Supplied) The main pitch will feature rugby matches throughout the day, including a mixed touch game to kick off proceedings at 1pm, which will be open to all abilities and ages. At 3pm, TeamLuke women's team will take on a North East Barbarians women's team, followed at 5pm by the TeamLuke men's team against North East Barbarians men. Luke's father Mark, a former player at Mowden Park who now plays at Darlington, said: "Luke loved his rugby and also enjoyed watching me play. There will be giant inflatables (Image: Supplied) "We started the charity as a legacy with the £125,000 we raised for him to go on a drug trial in Barcelona, which unfortunately he didn't make. "Since then we have raised double that and the latest funday is a natural progression of our charity work. "Over the years the rugby community has been spectacular in its support and we are really looking forward to welcoming families to the event." Public admission is just £2. Fun for all (Image: Supplied) There will be fun for the whole family (Image: Supplied) Team Luke Bell (Image: Supplied) There will be giant inflatables (Image: Supplied) (Image: Supplied)
Yahoo
08-05-2025
- Yahoo
East Bay family shocked to find van stolen after toddler's cancer treatment
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways OAKLAND, Calif. - Parents of an East Bay toddler receiving cancer treatment in Oakland were shocked to learn their van had been stolen after leaving a doctor's appointment this week. Toddler had just finished chemo round What we know Jia Kim, 3, is battling neuroblastoma. She and her family were at Kaiser Oakland on Monday when they discovered that their minivan was gone from a hospital parking structure across the street from the clinic where the young girl was receiving treatment. "Jia recently finished a very intense round of chemotherapy for her cancer," her mother, Dena Kim, said. Dena Kim and her husband, Hoya Kim, said they parked in the same structure as usual at 3510 Broadway. "We were exhausted — emotionally, physically — hungry, tired, ready to go home," Dena said. "We went up to the parking garage, to the sixth floor where we parked, and we couldn't find our minivan anywhere." The couple searched the entire garage but couldn't locate their 2019 Honda Odyssey minivan, which they purchased last year. It was gone. They say Kaiser security staff also searched but found nothing. "Finally, I just called police. The police officer came and took a report," Dena Kim said. "The security department here refused to check the footage or just confirm someone had taken it out of the garage." The Kims said they ended up stranded for hours before they could get back to their home in Pinole. They shared their story to highlight the impact of vehicle theft on victims — especially those already dealing with medical crises. Oakland police reported 10,439 vehicle thefts in the city in 2024. From Jan. 1 through May 7, 2024, about 3,755 vehicles were stolen. For the same period this year, that number has decreased to about 2,016. Stolen van located Dig deeper Early Wednesday, Dena Kim said an officer called to say the minivan had been found near Fourth and Folsom streets, close to Jack London Square. The license plate was missing. "We're just really frustrated that Kaiser has not prioritized — or the city has not prioritized — making sure the people who are coming here, the people that are most vulnerable, are kept safe," she said. Added her husband, "I just don't understand what kind of person comes to a hospital parking lot and steals a car with two car seats and disabled mark." Kaiser sent the following statement, "We work hard to make sure our members and visitors are safe and that their belongings are secure on our medical campuses. It is disgusting that car thieves would target a place of healing, where families are getting care and are often at their most vulnerable. Our security teams are investigating this theft and are working with the Oakland Police Department. We extend our thoughts to the family and welcome the opportunity to connect with them further to offer support." A family friend of the Kim family set up a GoFundMe to help Jia battle neuroblastoma. Jana Katsuyama is a reporter for KTVU. Email Jana at Call her at 510-326-5529. Or follow her on Twitter @JanaKTVU and read her other reports on her bio page.
